MT Group

What MT Group does

MT Group is a Los Angeles-based biospecimen Contract Research Organization (CRO) founded in 2003 that designs and executes prospective custom collections of human biological samples for pharmaceutical, biotechnology, and diagnostic companies. The company operates a network of more than 150 actively screening clinical collection sites across the US with growing international presence in South America, Europe, and Asia, serving clients in 25+ countries. Its product offerings span fresh, frozen, and FFPE tissue, whole blood, plasma, serum, PBMCs, WBCs, biofluids, and matched tissue sets, executed under IRB-approved collection protocols on a prospective (rather than banked) basis.

The company differentiates through its proprietary 'MT Level' comprehensive clinical annotation framework, which provides detailed donor metadata on clinical characteristics, and through a consultative sales approach backed by quality guarantees. Founded by Tom Moss and Marc Siegel, both with 30+ years of healthcare industry experience and prior co-founding experience at BIS Laboratories, MT Group operates a project-based custom collection model, with each project scoped to specific donor criteria and minimum subject counts. The company has completed more than 5,000 customized biospecimen collections and was named a Top 10 CRO by PharmaTech Outlook in 2021.

MT Group is privately held, founder-owned, and bootstrapped with a reported headcount of 11-50 employees. The business is currently expanding its therapeutic portfolio into autoimmune, dermatology, and neurodegenerative disease biospecimens, alongside building capabilities for matched tissue and liquid biopsy programs targeting early cancer detection and minimal residual disease applications. The revenue model is project-based custom collection work priced per engagement, with go-to-market driven by consultative selling into biopharma, biotech, and diagnostic client R&D teams.

Name

MT Group

Legal name

MT Group

Website

https://mtgroupbio.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

MT Group is a Los Angeles-based biospecimen CRO that designs and executes prospective custom collections of human tissue, blood, and biofluid samples for pharmaceutical, biotechnology, and diagnostic companies through a network of 150+ collection sites.

Ownership category

akta.pro rank

Product category

Biospecimen CRO Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

Keywords

• Biospecimen procurement services
• Custom biospecimen collections
• Human tissue procurement
• Liquid biopsy biospecimens
• Translational research services

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

1. Custom Biospecimen Collections: MT Group designs, manages, and executes prospective custom collection of human biological samples (tissue, blood, plasma) to exact study specifications for pharmaceutical, biotech, and diagnostic research clients. Revenue is generated through project-based fees for custom collection services, with studies typically requiring 10+ subjects.
2. Retrospective Specimen Sourcing: Provides access to banked/archived biospecimens including FFPE tissue blocks, frozen tissue, plasma, and matched specimen sets from their curated repository. Retrospective specimens typically delivered within 2-4 weeks.
3. Longitudinal Study Services: Serial sample collection services tracking patients over time through disease progression, treatment, remission, and potential relapse. Includes 95%+ patient retention rates achieved through coordinated standard-of-care visits and proactive engagement.
4. FFPE Tissue and Repository Services: Dual pathologist-reviewed FFPE blocks with validated clinical data. Includes tumor content verification (minimum 40% guarantee), quality replacement guarantee, and matched specimen set sourcing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

MT Group is a biospecimen Contract Research Organization (CRO) that designs and executes prospective custom collection of human biological samples — including fresh, frozen, and FFPE tissue, plasma, serum, whole blood, buffy coat, urine, saliva, and swabs — for pharmaceutical, biotechnology, and diagnostic R&D clients. Every collection is built around study-specific inclusion/exclusion criteria, IRB-approved protocols, and processing standards, and is delivered with proprietary "MT Level" comprehensive clinical annotation covering demographics, treatment history, response, and outcomes. Specimens are sourced through a network of 150+ IRB-approved collection sites in the United States with growing international reach in South America, Europe, and Asia.

Product overview

MT Group is a biospecimen Contract Research Organization (CRO) offering prospective customized biospecimen collection services for pharmaceutical, biotechnology, and diagnostic companies. The core offering combines prospective specimen collection (tissue, blood, plasma, serum, urine, saliva, swabs) with comprehensive "MT Level" clinical metadata annotation. Key products include: Custom Collections for study-specific procurement design; Liquid Biopsy Biospecimens for cfDNA/ctDNA/CTCs; Tissue Samples in Fresh, Frozen, and FFPE formats; Cancer and Autoimmune Disease Biospecimens; Matched Biospecimen Sets pairing tumor tissue with plasma/buffy coat; Longitudinal Collections with 95%+ patient retention; and IO-Experienced Biospecimens from checkpoint inhibitor-treated patients. Services are delivered through a 150+ site network across the US and internationally.

Differentiator

Problem solved

Functional benefit

Products and services

• Custom Biospecimen Collections Prospectively designed biospecimen collection programs customized to exact study specifications, including inclusion/exclusion criteria, processing protocols, and clinical data requirements, for pharma, biotech, and diagnostic clients.
• Tissue Samples (Fresh, Frozen, FFPE) Tumor and normal tissue specimens in multiple preservation formats: fresh tissue for viability-dependent applications, frozen tissue for genomic/proteomic studies, and FFPE blocks for histopathological analysis and molecular profiling.
• Blood Samples (Plasma, Serum, PBMCs) Whole blood and derived products including plasma, serum, buffy coat, and peripheral blood mononuclear cells collected under standardized protocols for biomarker, immune profiling, and molecular analyses.
• Liquid Biopsy Biospecimens Blood-derived specimens including plasma, serum, buffy coat, and whole blood collected using specialized tubes (Streck, PAXgene, CellSave) for cfDNA, ctDNA, and CTC analysis supporting liquid biopsy assay development.
• Cancer Biospecimens Ethically sourced cancer tissue and blood specimens across solid tumor types (breast, lung, colorectal, pancreatic, ovarian, etc.) with comprehensive clinical annotation, treatment history, and molecular biomarker data for translational oncology research.
• Autoimmune Disease Biospecimens Biospecimens from patients with autoimmune and inflammatory conditions including ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriasis, lupus, and type 1/2 diabetes, with comprehensive clinical annotation including treatment history and response data.
• IO-Experienced Biospecimens Biospecimens from patients treated with immune checkpoint inhibitors (PD-1/PD-L1 inhibitors, CTLA-4 inhibitors) and combination therapies, enabling immuno-oncology research, biomarker discovery, and resistance mechanism studies.
• Matched Biospecimen Sets Paired tissue and blood specimens from the same patient (FFPE tumor + plasma + buffy coat) enabling concordance studies between tissue-based and liquid biopsy assays for companion diagnostic development.
• Longitudinal Biospecimen Collections Serial specimen collection services following patients over time from diagnosis through treatment, remission, and potential relapse, achieving 95%+ retention rates for tracking disease progression and treatment response.
• COVID Biospecimen Collections Prospective COVID-19 and respiratory disease biospecimen collections including active infection, breakthrough infection, and recovered patients with comprehensive clinical metadata including symptomology, comorbidities, and vaccination history.
• Fresh Tissue Procurement Fresh tumor tissue procurement with documented collection-to-processing protocols ensuring optimal cell viability, with particular strength in tumor and inflammatory bowel disease tissue.
• Control Biospecimens Matched healthy control specimens with demographic and clinical matching criteria (age, sex, smoking status, BMI) for translational biomarker studies and assay validation.
• Site Network Access Network of 150+ IRB-approved biospecimen procurement sites across the US plus growing international reach in South America, Europe, and Asia, including academic centers, community hospitals, and specialty practices enabling diverse patient population access.

Quantifiable outcome

• Surpassed 5,000 customized biospecimen collections completed for translational research sponsors
• +4 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Umoe Advanced CompositesminorStrategic or Co-development Partner · 23 January 2026Umoe Advanced Composites was selected by MT Group to supply four 20-foot hydrogen storage containers for a hydrogen production facility in Vilnius, Lithuania, developed by Miesto Gijos. The facility will fuel 16 public transport buses, replacing diesel vehicles and cutting an estimated 1,414 tonnes of CO₂ emissions annually. The hydrogen refueling station is expected to be operational in the second half of 2026.

Scale indicators8 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• iSpecimen: Marketplace and biospecimen procurement platform connecting researchers with hospitals and biobanks for human biospecimens; competes with MT Group on demand-driven specimen access, though with a lighter-touch, marketplace-style model.
• BioIVT: One of the largest commercial biospecimen CROs globally, supplying human tissue, biofluids, and cellular products to pharma/biotech/diagnostic R&D; competes head-on with MT Group across prospective collections, biorepository services, and matched specimen sets.
• Cureline: Global biospecimen CRO providing prospective and retrospective human biospecimens for translational research, including oncology and rare disease collections—closely comparable in customer segments and offerings.
• Boca Biolistics: Biospecimen CRO specializing in custom human specimen collection for research, including cancer tissue, blood products, and matched specimens—comparable in scale and specialty focus to MT Group.
• Discovery Life Sciences: Biospecimen and bioanalytical CRO offering biospecimen procurement, custom collections, and specialty testing—directly comparable to MT Group's custom biospecimen and tissue procurement offerings, with a larger scale footprint.
• Precision for Medicine: Specialty CRO with a biospecimen/procurement arm serving biomarker-driven drug development, including biorepository, prospective collections, and multi-omic sample procurement—highly analogous to MT Group's translational CRO model.
• Indivumed (now Crown Bioscience): Specialty oncology biospecimen CRO with deep tissue and clinical data annotation capabilities; highly comparable to MT Group's oncology biospecimen and clinical annotation value proposition.
• Asterand Bioscience (now part of BioIVT): Historically a leading human tissue biospecimen CRO and now integrated into BioIVT; directly comparable in FFPE, frozen tissue, and matched blood/tissue offerings with deep clinical annotation.
• Tissue Solutions: Boutique biospecimen CRO specializing in custom human tissue procurement for pharma/biotech—similar scale and operating model to MT Group, including custom collections and ethically sourced samples with clinical annotation.

Broad incumbents

• LabCorp Drug Development (now Fortrea): Large incumbent CRO and central laboratory with biospecimen collection, biorepository, and bioanalytical services embedded in a broader clinical trial services portfolio; competes with MT Group for translational biospecimen work, especially for large pharma programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/the-mt-group
• Facebookfacebook.com/mtgroupbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MT Group